Novo Nordisk (NVO) Hit By Lowered Guidance

"Our second-largest detractor in the quarter was Novo Nordisk A/S (NYSE:NVO) -19.6%. NVO lowered its guidance due to several factors, including persistent use of compounded GLP-1 medications, slower- than-expected market expansion for obesity treatments, and heightened competition from Eli-Lilly's tirzepatide-based therapies. We welcome the recently announced changes to senior management and the company's new focus on operating efficiency. Novo Nordisk A/S (NYSE:NVO) is not on our list of 30 Most Popular St ...